Pernix Therapeutics Announces Positive Phase IV Results of Silenor® vs. Zolpidem Head-to-Head Arousability Study
16 juin 2016 08h00 HE
|
Pernix Therapeutics Holdings, Inc.
Data demonstrated that Pernix Therapeutics’ Silenor® 6 mg was superior to zolpidem 10 mg on all measures evaluated. Study results presented at SLEEP 2016 international meeting MORRISTOWN, N.J.,...